BioCentury | May 11, 2018
Strategy

Takeda hits the gas

...first-in-class candidates in Phase II, including IPlex mecasermin rinfabate (SHP607) for chronic lung disease, and SHP611...
...of insulin-like growth factor-1 (IGF-1) and its principal binding protein IGF binding protein 3 (IGFBP3). SHP611...
BioCentury | Mar 31, 2018
Strategy

Refashioning Takeda

...that is in Phase III testing in Japan to treat convulsive seizures. Shire does have SHP611...
BioCentury | Jul 21, 2014
Strategy

AbbVie's plan B

...for MPS-IIIA ( Sanfilippo A syndrome). SHP611 is in Phase I/II testing for metachromatic leukodystrophy. SHP611...
BioCentury | Nov 18, 2013
Strategy

Shire goes vertical

...HNS ) that is in Phase I/II testing for mucopolysaccharidosis IIIA, or Sanfilippo syndrome. SHP611...
...of Sanofi (Euronext:SAN; NYSE:SNY) has marketing rights in Japan and certain Asian Pacific countries SHP611 (HGT 1110...
BioCentury | Dec 24, 2012
Product Development

Shire homes in

...mucopolysaccharidosis (MPS). These products are delivered intravenously. Shire is exploring intrathecal delivery of Elaprase and HGT 1110...
BioCentury | Nov 12, 2012
Clinical News

HGT 1110: Phase I/II started

...open-label, dose-escalation, European Phase I/II IDEAMLD trial to evaluate 10, 30 and 100 mg intrathecal HGT 1110...
...Orphan Drug designation in the U.S. and EU. Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Product: HGT 1110...
BioCentury | Aug 9, 2010
Strategy

Shire Early and Late

...I SPD547 Guanfacine using CarrierWave technology to create abuse-resistant formulations ADHD Start Ph I in HGT 1110...
Items per page:
1 - 7 of 7